Associate Aydin Harston is quoted in a STAT article on the impact of the United States-Mexico-Canada Agreement (USMCA) on drug prices. The article reviews the concern by some over a provision in the USMCA that grants ten years of exclusivity to biologic drugs, and how it will potentially influence drug costs and competition in the U.S. The provision would prevent companies from selling biosimilar drugs in Mexico and Canada for a decade after a drug company launches a branded biologic. Currently, biologics only have five years of exclusivity in Mexico and eight years in Canada. In the U.S., biologics get 12 years of exclusivity.
The article, "NAFTA 2.0's impact on drug prices is more complicated than some Democrats are implying," by Ike Swetlitz, can be read on the STAT site here.
